• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models – Science Translational Medicine

Aug 7, 2024 | Publications

Click here to view...

A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation

Jul 24, 2023 | Publications

Click here to view...

A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned – PLOS Pathogens

Apr 19, 2023 | Publications

Click here to view...

Evaluation of repRNA vaccine for induction and in utero transfer of maternal antibodies in a pregnant rabbit model – Molecular Therapy

Mar 24, 2023 | Publications

Click here to view...

Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen — Tuberculosis

Feb 1, 2023 | Publications

Click here to view...

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis – Vaccines 2023

Feb 1, 2023 | Publications

Click here to view...
« Older Entries

Recent Posts

  • Providence Swedish Neuroscience Institute (PSNI) Reaches Milestone in Reducing Global Burden of Glioblastoma
  • A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
  • KING5 Seattle Healthlink Feature: Seattle-based group testing new immunotherapy approach to treat deadly form of brain cancer
  • HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial
  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow